Vlad Coric, Biohaven CEO

Fresh off $11.6B sale to Pfiz­er, New Bio­haven hits Phase III set­back just weeks af­ter Vlad Coric chalked up promise

When Pfiz­er bought up Bio­haven’s mi­graine port­fo­lio in the largest M&A deal of the year ear­li­er this month, Bio­haven CEO Vlad Coric promised the rest of the pipeline, which will live on un­der the um­brel­la of New Bio­haven, still has a lot to of­fer. But that vi­sion took a dent Mon­day as the drug­mak­er re­vealed it’s once again flopped on tro­r­ilu­zole.

The glu­ta­mate reg­u­la­tor failed to meet the pri­ma­ry end­point on a Phase III study in pa­tients with spin­ocere­bel­lar atax­ia, an in­her­it­ed dis­or­der that im­pairs a per­son’s abil­i­ty to walk, speak and swal­low. SCA can al­so lead to pre­ma­ture death.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.